Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US

Cancer

Volumn 109, Issue 6, 2007, Pages 1082-1089

  Aballéa, Samuel ^a,g   Chancellor, Jeremy V M ^a   Raikou, Maria ^b   Drummond, Michael F ^a,c   Weinstein, Milton C ^a,d   Jourdan, Sophia ^e   Bridgewater, John ^f  

^a Health Economics and Outcomes Research   (United Kingdom)

^b LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^c UNIVERSITY OF YORK   (United Kingdom)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^e SANOFI   (France)

^f ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^g Beaufort House ^*  (United Kingdom)

Author keywords

Colon cancer; Cost effectiveness; Oxaliplatin; Survival analysis

Indexed keywords

FLUOROURACIL; FOLINIC ACID; OXALIPLATIN;

ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER STAGING; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COLON CANCER; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DISEASE FREE SURVIVAL; FEMALE; HEALTH CARE COST; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MEDICARE; NAUSEA; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; SURVIVAL ANALYSIS; UNITED STATES;

EID: 33947267505     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22512     Document Type: Article

References (31)

1. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350:2343-2351.
2. de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years. J Clin Oncol. 2005;23(16S, part I of II):246S. Abstract 3501.
3. Brown ML, Nayfield SG, Shibley LM. Adjuvant therapy for stage III colon cancer: economics returns to research and cost-effectiveness of treatment. J Natl Cancer Inst. 1994;86: 424-430.
4. Norum J, Vonen B, Olsen JA, Revhaug A. Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma. A cost-effectiveness analysis. Ann Oncol. 1997;8:65-70.
5. Bonistalli L, Bardelli F, Costantini M, Trallori G, d'Albasio G, Messori A. Adjuvant chemotheraphy in patients with resectable stage III colon cancer: lifetime cost-effectiveness and cost-utility analysis. Cancer J. 1998;11:39-47.
6. Koperna T, Semmler D. Innovative chemotherapies for stage III colon cancer: a cost-effectiveness study. Hepatogastroenterology. 2003;50:1903-1909.
7. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press; 1996.
8. Gelber RD, Goldhirsch A, Cole BF. Parametric extrapolation of survival estimates with applications to quality of life evaluation of treatments. International Breast Cancer Study Group. Control Clin Trials. 1993;14:485-499.
9. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med. 1995;122:321-326.
10. Ramsey SD, Andersen MR, Etzioni R, et al. Quality of life in survivors of colorectal carcinoma. Cancer. 2000;88:1294-303.
11. Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care. 2005;43:736-749.
12. Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care. 2005;43:203-220.
13. Lin DY, Feuer EJ, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-up data. Biometrics. 1997;53: 419-434.
14. Chaudhary MA, Stearns SC. Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. Stat Med. 1996;15:1447-58.
15. Sargent DJ, Adjuvant Colon Cancer Endpoints (ACCENT) Group. Endpoints for Colon Adjuvant Clinical Trials. (CACT): recommendations based on individual patient data (IPD) from 20898 patients (pts) and 18 randomized trials. J Clin Oncol (Suppl). 2005;23(16S Part I of II):249s. Abstract 3512.
16. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352-358.
17. de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/LV in the adjuvant treatment of stage II and stage III colon cancer: efficacy results with a median follow-up of 4 years. J Clin Oncol. 2005;23(16S, Part I of II):246S. Abstract 3501.
18. Wolmark N, Wieand S, Kuebler JP, et al. A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07. J Clin Oncol (Meeting Abstracts). 2005;23:LBA3500.
19. Sargent D, Wieand S, Goldberg R.3 Year DFS vs. 5 year OS as an endpoint for adjuvant colon cancer studies: data from randomized trials. Available at URL: http://www.fda.gov/cder/drug/cancer_endpoints/sargent/sld001.htm. Accessed on 15-6-2004
20. Surveillance Epidemiology and End Results (SEER) Program. SEER*Stat Database: Incidence-SEER 17 Regs Public-Use, Nov 2005 Sub (1973-2003 varying). National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch. Available from URL: www.seer.cancer.gov Accessed on 10-10-2006.
21. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
22. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004; 22:23-30.
23. Schrag D. The price tag on progress-chemotherapy for colorectal cancer. N Engl J Med. 2004;351:317-319.
24. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making. 2000;20:332-342.
25. Ubel PA, Hirth RA, Chernew ME, Fendrick AM. What is the price of life and why doesn't it increase at the rate of inflation? Arch Intern Med. 2003;163:1637-1641.
26. Eichler H-G, Kong SX, Gerth WC, Mavros P Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7:518-528.
27. Matasar MJ, Sundararajan V, Grann VR, Neugut AI. Management of colorectal cancer in elderly patients: focus on the cost of chemotherapy. Drugs Aging. 2004;21:113-133.
28. Messori A, Bonistalli L, Costantini M, Trallori G, Tendi E. Cost effectiveness of adjuvant intraportal chemotherapy in patients with colorectal cancer. J Clin Gastroenterol. 1996; 23:269-274.
29. Launois R, Reboul-Marty J, Henry B, Bonneterre J. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine. Pharmacoeconomics. 1996;10:504-521.
30. Grunberg SM, Srivastava A, Grunberg KJ, Weeks J. Intensity of chemotherapy-induced emesis and overall survival as determinants of a global utility score. Support Care Cancer. 2002;10:624-629.
31. Cook J, Richardson J, Street A. A cost utility analysis of treatment options for gallstone disease: methodological issues and results. Health Econ. 1994;3:157-168.